Corporate Information

Company Profile

We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Our BioSeizer lipid formulation technology enables both local sustained release and fast onset of APIs at the site of disease or injury with increased pharmacokinetic (PK) control, made possible by customization of lipid layers. BioSeizer is utilized in our TLC599, TLC399 and TLC590 programs. Our NanoX active drug loading technology enables better toxicity profiles, potential for reduced dosing frequency, and enhanced distribution of liposome-encapsulated APIs to the desired site. We believe NanoX is capable of loading over 50 various compounds and is applied to our TLC178 program.

We believe our technologies can be used with a broad range of APIs and enable a simplified and scalable manufacturing process. Because our product candidates use already approved APIs, we are eligible to utilize the streamlined 505(b)(2) regulatory pathway for approval in the United States. We have used our proprietary technology platforms to assemble a diverse product candidate portfolio that targets significant areas of unmet medical need in pain management, ophthalmology and oncology.

Our team has over 150 years of domestic and global experience in lipids and other life sciences products and drug development expertise. Their accomplishments include gaining the approval of two generic lipid formulation products marketed in Asia. We are headquartered in Taipei, Taiwan, with offices in Hsinchu, Hong Kong, Leiden, Melbourne, Shanghai, South San Francisco and Tokyo.

Company Name

Taiwan Liposome Company, LTD. (TLC)

Stock Code

NASDAQ: TLC
TPEx: 4152

Industry

Biotechnology

Principal activities

Development of novel nanomedicines that maximize the potential of our proprietary LipAD™ lipid-assembled delivery system to enable sustained release and/or targeted deliveries that reduce toxicity and improve efficacy

Chairman

Dr. Keelung Hong

President

George Yeh

Principal Office

2F No. 3 Yuanqu Street, Nangang District, Taipei City, Taiwan

Number of Employees

165

(As of September 30, 2018)

Stock Transfer Agent

Common Share Transfer Agent:
Transfer Agent Department of SinoPac Securities Corp.

ADR Depositary Bank:
JPMorgan Chase Bank, Taipei Branch

Auditors

PricewaterhouseCoopers, Taiwan

Legal Advisors

K&L Gates
Cooley LLP

Telephone Number

+886 (0)2 2655 7377

Fax Number

+886 (0)2 2655 7366

Email Address

ir@tlcbio.com